Tesamorelin mastery course
Unit 7 of 11
Liver fat: the NAFLD evidence
The best-supported use beyond the label is fatty liver in HIV. Two randomized trials show tesamorelin meaningfully redu…
The promising second act: reducing liver fat, still off-label
The best-supported use beyond the label is fatty liver in HIV. Two randomized trials show tesamorelin meaningfully reduces liver fat, and a biopsy substudy hints it slows disease progression, all through the same visceral-fat mechanism.
This unit covers the pathobiology of HIV-associated fatty liver, the Stanley 2014 and 2019 trials, the visceral-to-liver mechanism, and why strong data in a narrow population is still not the same as an approved indication.